IPO Timeline
Broker Results (T-2)
2021-12-28
Some brokers release in afternoon
Grey Market (T-1)
2021-12-29
Afternoon
HKEX Allotment (T-1)
2021-12-29
Evening
Registrar Allotment (T-1)
2021-12-29
Evening
Listing Day (T)
2021-12-30
First day of trading
Company Overview
| Stock Name | 聖諾醫藥 - B |
|---|---|
| Stock Code | 02257 |
| Company Full Name | 聖諾醫藥 - B |
| Industry | 醫療保健 |
| Principal Activities | 主要從事生物制藥業務，包括核糖核酸干擾（RNAi）技術及多種療法的開發及商業化。 |
| Listing Date | 2021-12-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省蘇州市蘇州工業園星湖街218號A4樓415室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | https://www.sirnaomics.com/hk |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 65.90 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 44.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 49,688,600 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 77.9 |
|---|---|
| First Day Open | HK$ 65.9 |
| First Day Change | 18.21% |
| First Day Volume | 1252800.0 |
| First Day Turnover | 86073700.0 |
Use of Proceeds
| Use of Proceeds | 1、約229.1百萬港元（相當于約29.4百萬美元，占所得款項凈額的57.9%）將用于撥付發展及商業化STP705； 2、約61.8百萬港元（相當于約7.9百萬美元，占所得款項凈額的15.6%）將用于撥付STP707的開發； 3、約60.7百萬港元（相當于約7.8百萬美元，占所得款項凈額的15.4%）將用于撥付我們的GalNAc計劃產品，以及其他臨床前階段候選產品； 4、約29.1百萬港元（相當于約3.7百萬美元，占所得款項凈額的7.3%）將用于撥付其他臨床前候選藥物的研發； 5、約15.0百萬港元（相當于約1.9百萬美元，占所得款項凈額的3.8%）將用于一般企業及營運資金用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (5)
中国国际金融香港证券有限公司 CE AEN894
香港上海汇丰银行有限公司
Nomura International (Hong Kong) Limited CE AAF742
招商证券（香港）有限公司 CE AAI650
平证证券(香港)有限公司
Joint Bookrunners (7)
中国国际金融香港证券有限公司 CE AEN894
香港上海汇丰银行有限公司
Nomura International (Hong Kong) Limited CE AAF742
招商证券（香港）有限公司 CE AAI650
平证证券(香港)有限公司
Alpha Win Capital Limited CE BNI045
华盛资本证券有限公司 CE AUL711
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 昆明佳时清投资合伙企业(有限合伙) | 183,956,555 HKD | — | 37.02% | — | 6 months | 2022-06-30 |
| 2 | 浙江健新原力制药有限公司 | 38,969,965 HKD | — | 7.84% | — | 6 months | 2022-06-30 |
Directors & Management
| Chairman | 潘洪輝 |
|---|---|
| Company Secretary | 袁潤廷 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 陸陽及家族成員(11.37%);戴曉暢(9.32%);上海沖石企業管理合夥企業(5.13%) |
|---|
IPO Timeline
